OBJECTIVE:To probe into the evaluation method on technological capability of pharmaceutical enterprises.METHODS:The connotation of pharmaceutical enterprises'technological capability was expounded;the characteristics of each evaluation index,i.e.output index and input index of technological capability of pharmaceutical enterprises were ana?lyzed.RESULTS:Detailed and complete information on the evaluation of pharmaceutical enterprises'technological innovation capability was unavailable from the output index and input index only.CONCLUSION:The evaluation on pharmaceutical enterprises'technological innovation capability should include more comprehensive,more dynamic and more integral evaluation indexes.

OBJECTIVE:To cultiveate and development of Research &Development(R &D)abilities for new drugs for Chinese pharmaceutical enterprises.METHODS:The experiences on new drugs' R&D of some Indian pharmaceutical enterprises were analyzed.RESULTS &CONCLUSION:To improve R &D abilities for new drugs,Chinese pharmaceutical enterprise should try to explore effective ways and measures by not only emphasizing the strategic value of R&D for new drugs,but also strengthening the cooperation with outside,attracting the overseas talents,cultivating the integrative capa-bility,etc.

OBJECTIVE:To recommend the development strategies for small and medium-size pharmaceutical commercial enterprises. METHODS: We analyzed the development and change of the macro-policies and industrial surroundings and discussed different strategies available for small and medium-size pharmaceutical commercial enterprises. RESULTS & CONCLUSIONS: Among those suitable strategies, which include scale enlargement, service differentiation, and countryside & community market expansion etc, small and medium enterprises should choose different kinds of strategies according to their special characteristics. Meanwhile they should incessantly enhance their real strength and spare no effort to cultivate their own competitive advantage to seek survival and development.

OBJECTIVE：To provide reference for accelerating the process of prescription outflow in China by using “Internet+ medicare”. METHODS ：Based on stakeholder perspective ，the stakeholder model of prescription outflow was constructed under the background of “Internet + ”. By analyzing stakeholders （hospital，patient，government，drugstore and third-part consultation platform）who impeded the prescription outflow and their demands ，the obstacles and causes of promoting prescription outflow under the background of “Internet+”were summarized to put forward relevant countermeasures and suggestions. RESULTS & CONCLUSIONS：“Internet+Medicare”accelerated the process of prescriptions outflow by improving the convenience in each links of medical treatment ，but there were still obstacles in prescription source ，patient flow ，supporting policies and system construction to continue promoting prescription outflow. The reason lied in the pressure of hospital operation and the diagnosis demand of doctors；the treatment demand of patients could not be satisfied by the receiving party of prescription outflow ；the difficulty of government supervision and system construction ；immature supervision mode of the third-party consultation platform and online pharmacies，and the platform technology research and development to be break through. To continue promoting prescription outflow under the background of “Internet + ”needs to strengthen top-level design ，establish supporting systems ，break the regional restrictions，build a unified and standardized prescription circulation information platform ；formulate the prescription outflow assessment standard and encouragement mechanism of hospital ，enhance the ability of the third-part platforms and pharmacies to undertake the prescription ，strengthen the publicity and education of patients ，enhance their channel awareness and risk awareness. The exploration mode of prescription outflow in which all stakeholders develop together and cooperate with each other is formed finally so as to promote the outflow of prescription.

OBJECTIVE：To put forward some suggestions for the implementation of OTC monograph in China. METHODS ： Literature research was used to comprehensively review the concept ，emergence and development ，function of OTC monograph in USA；referring to experience in USA ，the necessity and feasibility of monograph system for OTC registration and evaluation in China were explored ，and some suggestions were put forward to the implementation of OTC monograph in China. RESULTS & CONCLUSIONS：OTC monograph in USA refers to the regulatory standards that should be followed when selling OTC products not included in new drug applications. The monograph originates from the re-evaluation project of the effectiveness of OTC drugs ， which plays a special role in accelerating the drug marketing and promoting product innovation. The OTC monograph system is necessary to help to optimize the OTC registration and evaluation ，but at present ，the conditions to establish and implement OTC monograph are not yet ripe in China. Based on the optimization of resource allocation and infrastructure construction ，national OTC drug management experience ，OTC monograph can play a full part in OTC registration and evaluation ，in terms of carrying out in-depth research ，taking pilot test ，improving risk management system and enhancing drug review resource allocation ability.